Clinical Trial Update: 17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease [Phase 2]

View source ↗

Summary

Phase 2 trial of tanespimycin (17-AAG) for kidney tumors in patients with von Hippel-Lindau disease completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hippel-lindau Disease
• Kidney Cancer

Drugs mentioned

• tanespimycin (17-N-allylamino-17-demethoxygeldanamycin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Hippel-Lindau Disease, Kidney Cancer | Phase 2 | Status: COMPLETED | Results posted: 2011-09-29